On a per-share basis, the Durham, North Carolina-based company said it had a loss of 19 cents.
The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.
The drugmaker posted revenue of $12.5 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $3.8 million.
BioCryst shares have increased 19 percent since the beginning of the year. The stock has increased 15 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX
Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.